KBC Group’s Teva Pharmaceuticals TEVA Stock Holding History

KBC Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.67M	Hold	55,414	–	–	﹤0.01%	683
2025 Q4	$1.73M	Hold	55,414	–	–	﹤0.01%	623
2025 Q3	$1.12M	Hold	55,414	–	–	﹤0.01%	665
2025 Q2	$929K	Buy	55,414 +8,498	+18%	+$137K	﹤0.01%	672
2025 Q1	$721K	Buy	46,916 +9,753	+26%	+$174K	﹤0.01%	686
2024 Q4	$819K	Buy	37,163 +11,220	+43%	+$204K	﹤0.01%	772
2024 Q3	$467K	Hold	25,943	–	–	﹤0.01%	727
2024 Q2	$422K	Hold	25,943	–	–	﹤0.01%	736
2024 Q1	$366K	Buy	25,943 +10,733	+71%	+$135K	﹤0.01%	755
2023 Q4	$159K	Sell	15,210 -6,166	-29%	-$57.6K	﹤0.01%	889
2023 Q3	$218K	Hold	21,376	–	–	﹤0.01%	819
2023 Q2	$161K	Buy	21,376 +8,628	+68%	+$70K	﹤0.01%	1006
2023 Q1	$113K	Hold	12,748	–	–	﹤0.01%	1164
2022 Q4	$116K	Hold	12,748	–	–	﹤0.01%	1151
2022 Q3	$103K	Hold	12,748	–	–	﹤0.01%	1175
2022 Q2	$96K	Hold	12,748	–	–	﹤0.01%	1240
2022 Q1	$120K	Hold	12,748	–	–	﹤0.01%	1141
2021 Q4	$102K	Sell	12,748 -27,743	-69%	-$250K	﹤0.01%	1178
2021 Q3	$394K	Sell	40,491 -12,473	-24%	-$117K	﹤0.01%	919
2021 Q2	$524K	Hold	52,964	–	–	﹤0.01%	1041
2021 Q1	$612K	Hold	52,964	–	–	﹤0.01%	1003
2020 Q4	$2.81M	Hold	52,964	–	–	﹤0.01%	974
2020 Q3	$478K	Hold	52,964	–	–	﹤0.01%	955
2020 Q2	$654K	Buy	52,964 +5,059	+11%	+$57.2K	﹤0.01%	905
2020 Q1	$430K	Buy	47,905 +21,811	+84%	+$223K	﹤0.01%	880
2019 Q4	$256K	Hold	26,094	–	–	﹤0.01%	1253
2019 Q3	$180K	Hold	26,094	–	–	﹤0.01%	1263
2019 Q2	$241K	Sell	26,094 -175,472	-87%	-$2.12M	﹤0.01%	1208
2019 Q1	$3.16M	Buy	201,566 +175,472	+672%	+$3.09M	0.03%	495
2018 Q4	$402K	Hold	26,094	–	–	﹤0.01%	973
2018 Q3	$562K	Sell	26,094 -15,000	-37%	-$348K	﹤0.01%	1070
2018 Q2	$1M	Sell	41,094 -26,082	-39%	-$532K	0.01%	802
2018 Q1	$1.15M	Buy	67,176 +24,312	+57%	+$475K	0.01%	736
2017 Q4	$812K	Sell	42,864 -6,524	-13%	-$98.1K	0.01%	861
2017 Q3	$869K	Sell	49,388 -335,623	-87%	-$7.55M	0.01%	840
2017 Q2	$12.8M	Buy	385,011 +334,327	+660%	+$10.3M	0.12%	198
2017 Q1	$1.63M	Buy	50,684 +9,360	+23%	+$319K	0.01%	705
2016 Q4	$1.5M	Buy	41,324 +31,276	+311%	+$1.25M	0.01%	724
2016 Q3	$463K	Buy	10,048 +1,300	+15%	+$67.8K	0.01%	984
2016 Q2	$440K	Buy	8,748 +625	+8%	+$33.3K	0.01%	911
2016 Q1	$435K	Hold	8,123	–	–	0.01%	873
2015 Q4	$533K	Sell	8,123 -1,114	-12%	-$68.8K	0.01%	780
2015 Q3	$522K	Sell	9,237 -23,099	-71%	-$1.5M	0.01%	764
2015 Q2	$1.91M	Sell	32,336 -16,360	-34%	-$1.01M	0.02%	567
2015 Q1	$3.03M	Sell	48,696 -20,429	-30%	-$1.19M	0.04%	423
2014 Q4	$3.98M	Buy	69,125 +68,011	+6,105%	+$3.79M	0.05%	409
2014 Q3	$60K	Sell	1,114 -165,412	-99%	-$8.76M	﹤0.01%	1198
2014 Q2	$8.73M	Buy	166,526 +141,301	+560%	+$7.22M	0.1%	250
2014 Q1	$1.33M	Sell	25,225 -4,561	-15%	-$211K	0.02%	591
2013 Q4	$1.19M	Sell	29,786 -6,057	-17%	-$239K	0.02%	625
2013 Q3	$1.35M	Hold	35,843	–	–	0.02%	610
2013 Q2	$1.41M	Buy	+35,843	New	+$1.4M	0.03%	579

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's TEVA Position: Q1 2026 in Review

KBC Group held its Teva Pharmaceuticals (TEVA) position steady in Q1 2026 at 55,414 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #683.

KBC Group first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.8M in Q2 2017. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

KBC Group held 55,414 shares of Teva Pharmaceuticals worth $1.67M as of Q1 2026.
KBC Group left its Teva Pharmaceuticals share count unchanged in Q1 2026.
Teva Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #683 holding.
KBC Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
KBC Group's Teva Pharmaceuticals position peaked at $12.8M in Q2 2017.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.